Kornimate/medical-research-clean huggingface dataset:
a prospective study examining the barriers to care for harris county cervical cancer patients

Conditions: Cervical Cancer

Summary: the goal of this behavioral research study is to look at the reasons that may prevent women from getting early treatment for their cervical cancer.

little is known about what prevents women with cervical cancer from getting early and possibly curative treatment. this study consists of a series of questionnaires that ask questions about religion; coping; access to health care; physical, emotional, and spiritual well-being; understanding of health questions; control; fear; anxiety; and other health beliefs to determine why some women delay coming in for check-ups and why some women do not complete their treatments. it is thought that health beliefs influence behavior practices and that by identifying these issues, things can be done to improve the health condition and results for these patients. you will be asked to complete a series of questionnaires at 2 specific time points: the first time point will be before treatment begins and the second time point will be within a month following completion of treatment. filling out the questionnaires should take about 45 minutes each time. you should have adequate time to complete these questionnaires during your clinic appointment. if you want to take part but are too ill to complete the questionnaires, you will be provided a pre-addressed, stamped envelope, so that you can mail them back to the study staff at your earliest convenience. this is an investigational study. this is an investigational study. up to 150 patients will be enrolled at lyndon b. johnson general hospital.

Eligibility criteria:
inclusion criteria: 1) all newly diagnosed cervical cancer patients through stage ivb presenting to the lyndon b. johnson general hospital (lbj) gynecologic oncology clinic. exclusion criteria: 1) patients who are not english or spanish speaking.

Keywords: cervical cancer cervix precancerous lesions cervical carcinoma in situ cis early cervical cancer detection and treatment barriers to care harris county questionnaire
d-vitamin and graves' disease; morbidity and relapse reduction

Conditions: Graves' Disease

Summary: the purpose of this study is to investigate the effects of vitamin d supplementation on morbidity and risk of relapse in patients with graves' disease.

in a multicentre trial, 260 patients with newly diagnosed graves ' disease will be randomized to cholecalciferol 70 mcg/day or placebo in a parallel group design. drop outs prior to 31th of december 2017 will be replaced. the intervention will continue during treatment with antithyroid drugs (atd), and for a period of 12 months after cessation of atd. blood samples will be collected at study entry, at 3 and 9 months, and at end of study. qol questionnaires on nine occasions through out the study period. in a subcohort of 80 participants detailed examinations of bone density and geometry, muscle strength and postural balance, immune tests (n=50), and measurements of arterial stiffness will be performed at study entry, and at 3 and 9 months after randomisation.

Eligibility criteria:
inclusion criteria: * a first time diagnosis of graves' hyperthyroidism within the last three months, confirmed by tsh below 0.01 iu/l, and t3 or t4 levels above the reference interval necessitating atd therapy * positive trab * speak and read danish * written informed consent exclusion criteria: * previously diagnosed hyperthyroidism * atd treatment initiated more than 3 months prior to inclusion * planned ablative therapy (radioactive iodine or thyroid surgery) * intake of more than 10 µg d-vitamin/day that the participant wishes to continue. * chronic granulomatous illness * persistent hypercalcemia (plasma calcium \> 1.40 mmol/l) * reduced kidney function (egfr \< 45 ml/min) * treatment with immunomodulatory drugs * active malignant disease * alcohol or drug abuse * pregnancy at inclusion * major comorbidity, making the participant unlikely to continuously receive trial intervention. * allergy towards the components in the d-vitamin or the placebo pills. * unable to read and understand danish * lack of informed consent.

Keywords: cholecalciferol vitamin d3 arterial stiffness quality of life bone density and geometry muscle strength and balance
collection of outcomes data for pregnant patients with cancer

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this study collects treatment and outcomes information on pregnant patients who are or were pregnant with cancer. gathering and storing health information on pregnant patients with cancer, may provide data for future research studies and improve patient care.

primary objectives: i. to collect, both prospectively and retrospectively, data on disease characterization, treatment and outcome for pregnant patients with malignancies seen at m. d. anderson cancer center. ii. to organize clinical information in order to support multifaceted queries of patient characteristics, treatment, and pregnancy outcome data and to facilitate correlation of these characteristics with patient outcome. iii. to have a single data repository, kept on a secure platform, that will integrate clinical information and research findings and serve as a secure archive for future research. outline: patients' medical records are reviewed prospectively and retrospectively.

Eligibility criteria:
inclusion criteria: * all pregnant patients with cancer and patients known to have been pregnant with a diagnosis of cancer are eligible, regardless of their diagnosis or treatment plan * patients may receive prenatal care from any obstetrician, but a consult with maternal fetal medicine is encouraged
study evaluating isovorin in advanced/recurrent gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of the study is to verify non-inferiority of survival time between isovorin/5-fluorouracil (1-lv/5fu) therapy and ts-1 therapy in patients with inoperable advanced or recurrent gastric cancer. secondary endpoints include response rates, duration of responses, time to progression (ttp) safety and quality of life (qol).


Eligibility criteria:
inclusion criteria: * gastric cancer diagnosed histologically or cytologically * normal organ function of bone marrow, heart, liver and kidney * age of 20-77 other inclusion applies exclusion criteria: * serious infection, heart disease, complication or organ disorder * ongoing administration of flucytosine * pregnant or breastfeeding women other exclusion applies

Keywords: gastric cancer advanced/recurrent gastric cancer
study on the therapeutic mechanisms of dithranol treatment in patients with chronic plaque psoriasis

Conditions: Psoriasis

Summary: dithranol (known in the u.s.a. as anthralin and in germany as cignolin) is one of the oldest and safest topical anti-psoriatic treatments. however, despite explorative investigations, the skin disease-clearing mechanisms of dithranol remain poorly understood (painsi et al, jddg 2015). the purpose of this study is to investigate the therapeutic mechanisms of dithranol in psoriasis.

skins biopsies from psoriatic skin and blood samples will be taken before (day 0) and at several time points after start (day 4, week 2-3, and week 6-7) of dithranol therapy to be subjected to an explorative analysis (see outcome measures). a total of maximal 15 psoriasis patients will be enrolled. normal lesion-adjacent skin from 10 patients undergoing surgery for non-inflammatory conditions will serve as control.

Eligibility criteria:
inclusion criteria: * males and females over 18 years of age * clinical diagnosis of chronic plaque psoriasis * dithranol treatment scheduled exclusion criteria: * systemic anti-psoriatic therapy (dmard, phototherapy and/or biologics) within 4 weeks of study entry (start of dithranol treatment) * topical treatment with steroids and or vitamin d3 analogues within 2 weeks of study entry (start of dithranol treatment) * autoimmune disorders * poor general health status * intolerance of dithranol * pregnancy and lactation period

Keywords: dithranol therapeutic mechanisms
tacrolimus versus prednisolone for the treatment of minimal change disease

Conditions: Minimal Change Disease

Summary: the purpose of this study is to compare the effectiveness of tacrolimus (prograf) versus prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease.

minimal change disease is a common cause of nephrotic syndrome in adults. standard treatment is with high dose steroids which is often effective in controlling the nephrotic syndrome but has a high morbidity due to the side effects of the steroids. there is also a high relapse rate,therefore many patients require long term steroid therapy to control their disease which has significant morbidity and mortality. some patients are or also become steroid resistant. there are studies showing the effectiveness of alkylating agents such as cyclophosphamide but the use of these drugs is limited by their toxicity, including increased rates of infection, cancers and infertility. tacrolimus (prograf) is a t-cell specific calcineurin inhibitor that shares similar immunosuppressive actions with cyclosporine a.in other glomerular diseases such as focal segmental glomerulosclerosis and membranous glomerulonephritis, prograf has been shown to be a very effective treatment for proteinuria. this may be due to the immunomodulatory effects on the underlying disease, but there may also be a direct effect of tacrolimus (prograf) on the podocyte, stabilising the actin cytoskeleton and therefore decreasing protein leak.therefore tacrolimus (prograf) is likely to be effective in reducing proteinuria in minimal change disease.it has also been shown to have a good side effect profile when used to allow the avoidance of steroids in transplantation.this study aims to prospectively study if tacrolimus (prograf) is effective as treatment for minimal change disease compared with standard therapy with steroids, and whether it has advantages in terms of side effect profile and prevention of relapse.

Eligibility criteria:
inclusion criteria: * patients with nephrotic syndrome (hypoalbuminaemia and protein creatinine ratio (pcr) \> 100units), secondary to minimal change disease. * age over 18. exclusion criteria: * hepatitis b, hepatitis c or hiv infection. * untreated infection. * females who are pregnant, breast feeding, or at risk of pregnancy and not using a medically acceptable form of contraception. * patients who have been treated with immunosuppression over the last 18 months. * patients who have had more than 3 relapses of nephrotic syndrome within 5 years. * any condition judged by the investigator that would cause the study to be detrimental to the patient.

Keywords: nephrotic minimal change tacrolimus prednisolone
is treatment of the intervertebral disc more effective at short-term than the nerve root in patients with a neck hernia?

Conditions: Contained Cervical Disc Herniation

Summary: pain management in a neck hernia relies initially on rest, physiotherapy, and/or oral medications. once these treatments have failed, different alternative procedures can be applied to relief pain. thermal treatment of the intervertebral disc (percutaneous cervical nucleoplasty; pcn) is the most often applied technique on the neck with a low risk of thermal damage. a variety of published studies have demonstrated this treatment to be both safe and effective. however, treatment of the nerve root (pulsed radio frequency; prf) is also a popular type of pain treatment. the application of prf is also a safe and useful intervention for neck pain. although these treatment types are described in the literature, the available evidence for efficacy is not sufficient to allow definitive conclusions on the optimal therapy to be made. the purpose of this study is to investigate which technique is the most effective in terms of pain relief on short term in patients with contained cervical disc herniation: pcn or prf?


Eligibility criteria:
inclusion criteria: * patients are legally competent and able to understand the nature, scope and aim of the clinical investigation and have given written informed consent to participate; * patients of either sex and of all races have been diagnosed with radiographically confirmed contained cervical disc herniation on mri at one level; * patients received a diagnostic block; * patients failed conservative therapy during at least six weeks; * patients have complaints of radicular pain with or without neck pain, corresponding the herniated level; * patients score \>=50 mm on 100 mm visual analogue scale for pain (vas-100 mm); * patients are able and willing to return for follow-up evaluations; * patients have a stable drug regime. exclusion criteria: * patients have contraindications for intervention with pcn or prf; * patients have been diagnosed with an extruded or sequestered disc fragment, spondylolisthesis, vertebral fracture or spinal stenosis; * patients have been diagnosed with uncovertebral or facet arthrosis; * patients underwent previous surgery or received any type of infiltrations at the indicated cervical level; * patients diagnosed with a contained cervical disc herniation \>1/3 spinal canal; * patients with radiographically confirmed loss of \>30% of disc height compared to adjacent level; * patients with evidence of severe disc degeneration; * patients suffer from uncontrolled psychological disorders; * patients suffer from unstable medical condition.

Keywords: nucleoplasty pulsed radio frequency herniated disc cervical percutaneous disc decompression cervical radiculopathy
persona mc vs attune total knee replacement study

Conditions: Knee Osteoarthritis

Summary: this study aims to compare clinical and functional outcomes of a cohort of patients that have undergone a medial congruent tkr to a similar cohort of patients that have undergone a conventional tkr and a cohort of control participants. our null hypothesis is that there will be no difference in the functional outcome (as assessed by gait analysis) between attune and persona mc tkr.

this cross sectional, post-operative comparator gait study aims to compare the functional and patient reported outcomes of patients that have undergone a mc tkr to an age, gender, bmi, pre-operative diagnosis with satisfactory clinical outcome at one year (oks \> 34) matched cohort of patients undergone a modern generation tkr which utilises a gradually reducing radius of curvature on the femoral component with conventional polyethylene (attune) to a tkr with gradually reducing radius of curvature on the femoral component but a medial congruent (mc) tkr design (persona).

Eligibility criteria:
inclusion criteria: 1. aged 18 years and above\* 2. have undergone primary total knee replacement for either: 1. osteoarthritis 2. avascular necrosis of the femur or tibia 3. report an oxford knee score greater than 34, obtained from usual clinical practice. oks above 34 represents (range 0-48, high representing good outcome) a good outcome post-surgery. 4. independent of study participation, patients received either commercially available zimmer biomet persona mc bearing or depuy synthes attune knee implants implanted in accordance with product labelling 5. 1-5 years post tkr surgery 6. an adequate understanding of written and verbal information in english in order to provide informed consent and answer the study questionnaires\* \* control participants will meet same inclusion criteria except no primary tkr and oks will not be required exclusion criteria: 1. history of infection in the replaced joint and/or other local/systemic infection that may affect the prosthetic joint 2. skeletal immaturity 3. neuropathic arthropathy 4. osteoporosis/any loss of musculature or neuromuscular disease that compromises the affected limb 5. severe instability secondary to the absence of collateral ligament integrity 6. pregnancy - routine clinical practice ensures that all female patients are asked whether they are pregnant and can safely receive x-rays or surgery as per standard consent forms 7. patient is a member of a protected population (e.g., prisoner, mentally incompetent, etc.) 8. patient has previously received partial or total knee arthroplasty for the ipsilateral knee 9. patients who are unable to give voluntary informed consent. 10. patients who are unable to walk unaided (post-surgery). 11. bmi \> 40 \*\* control participants will meet the same exclusion criteria as tkr patients 12. patients who suffer with cognitive impairment such as parkinson's or alzheimer's disease resulting in impaired mental capacity. 13. patients who are unable to walk unaided. 14. patients who suffer from dizzy spells or fainting episodes.

Keywords: total knee replacement total knee arthroplasty gait analysis
chemoreflex sensitivity in chronic kidney disease

Conditions: Chronic Kidney Disease; Cardiovascular Morbidity

Summary: cardiovascular morbidity and mortality are markedly increased in chronic kidney disease (ckd) and may be explained in part by sympathetic hyperactivity. impaired hyperoxic chemoreflex sensitivity (chrs) has been attributed to an increased sympathetic activity. the aim of the present study is to examine whether chemosensor function is altered in patients with stage 3 and stage 4 ckd.

impaired hyperoxic chemoreflex sensitivity (chrs) is assessed in patients with stage 3 ckd \[glomerular filtration rate (gfr) 30-59 ml/min/1.73 m2\], in patients with stage 4 ckd \[gfr 15-29 ml/min/1.73 m2\], as well as in patients without any evidence of ckd. chrs is measured by determination of the venous partial pressure of oxygen and the heart rate before and after deactivation of the chemoreceptors by inhalation of pure oxygen. the difference in the r-r intervals before and after inhalation divided by the difference in the oxygen pressures is calculated as the chrs. a chrs below 3.0 ms/mmhg is defined as pathological. it should be shown that using a simple clinical bedside test we provide the first evidence for impaired hyperoxic chemoreflex sensitivity in stage 3 and 4 chronic kidney disease. we thereby may lay the basis for future intervention studies assessing chemosensor function in these patients.

Eligibility criteria:
inclusion criteria: * patients suffering from cdk stage 3 (gfr 30-59 ml/min/1.73 m²) or stage 4 (gfr 15-29 ml/min/1.73 m²) * for the reference patients without evidence for cdk exclusion criteria: * patients with heart failure, history of myocardial infarction or instable angina pectoris, atrial fibrillation, hyperthyroidism, chronic pulmonary diseases, sleep apnoea syndrome, alcohol abuse and drug induced cardiomyopathy

Keywords: cardiovascular autonomic neuropathy chemoreflex sensitivity chronic kidney disease sudden cardiac arrest
adipokines in polycystic ovary syndrome

Conditions: PCOS; Reproductive Age

Summary: the aim of the study is to compare the concentrations of leptin, resistin, and omentin-1 in women across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome.

polycystic ovary syndrome (pcos) is the most prevalent endocrinopathy among reproductive-age women, characterized primarily by insulin resistance (ir), which has a prevalence of 35% to 80%. metabolic disturbances associated with pcos contribute to a higher incidence of cardiovascular diseases and endometrial cancer prior to menopause. the hyperinsulinemic-euglycemic clamp study is regarded as the gold standard for assessing insulin sensitivity; however, its clinical application is limited. alternative assessments, such as the homeostasis model assessment of insulin resistance (homa-ir) and fasting insulin or glucose tolerance tests, provide limited clinical utility. therefore, there is a pressing need for the identification of more precise and universal markers of insulin resistance. there is a need to elucidate the precise role of adipokines in the etiology of pcos and their association with insulin resistance, which is responsible for the development of adverse health-related complications. the aim of the study is to measure and compare the concentrations of selected adipokines: leptin, resistin, omentin-1 across three research groups: those with polycystic ovary syndrome without insulin resistance, those with polycystic ovary syndrome with insulin resistance, and women without polycystic ovary syndrome. the tests will be performed using immunoenzymatic methods (elisa) and the erba xl biochemical analyzer. the concentrations of the investigated substances will be measured and compared within the three research groups. statistical analysis will be conducted using spss statistics software.

Eligibility criteria:
inclusion criteria: * age 18-45 exclusion criteria: * previous removal of at least one ovary * treated diabetes of any type * diagnosed and treated metabolic diseases * diagnosed and treated autoimmune diseases * diagnosed and treated autoinflammatory diseases(edited)restore original

Keywords: insulin resistance polycystic ovary syndrome metabolic syndrome adipokines
optimal regimen in endovascular therapy in ischemic cerebrovascular disease based on clopidogrel resistance

Conditions: Ischemic Cerebrovascular Disease

Summary: 1. clopidogrel resistance is common in patients of ischemic cerebrovascular disease. 2. genetic polymorphisms are the most important factors to clopidogrel resistance. 3. the purpose of this study is to find the genes which are the related to clopidogrel resistance. 4. through gene sequencing, we can filter patient of clopidogrel resistance, so another drug maybe used to avoid the undesired efficacy.


Eligibility criteria:
inclusion criteria: * symptomatic ischemic cerebrovascular disease caused by intracranial atherosclerotic atherosclerosis research database. * 90 days had a stroke or transient ischemic attack is defined as symptomatic intracranial atherosclerotic atherosclerosis * stenosis ≥ 50% (mri or ct angiography). * intracranial vascular stenosis measured according to the method reported warfarin aspirin symptomatic intracranial disease research. exclusion criteria: * diffuse intracranial arterial stenosis. * cranial magnetic resonance imaging shows lesions as the branch artery blockage caused. * non-atherosclerotic lesions. * occurred within 6 weeks of vascular lesions in the region of intracranial hemorrhage. * potential cardiac thrombus source. * has concurrent intracranial tumors, intracranial aneurysm or arteriovenous malformation. * ipsilateral extracranial carotid or vertebral artery stenosis ≥ 50%; * known to heparin, aspirin, clopidogrel, anesthetics and contrast agents contraindications; * hemoglobin less than 10g/dl, platelet count \<100000/dl; * responsibility left after cerebral vascular-related serious neurological dysfunction (mrs ≥ 3); * international normalized ratio\> 1.5 * there are factors that can not be corrected by bleeding; * life expectancy \<1 year; * pregnant or lactating women; * indications commission determines that the patient is not suitable for the study treatment.

Keywords: ischemic cerebrovascular disease percutaneous transluminal angioplasty and stenting clopidogrel resistance